|
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial.
PMID 39999660 · Atherosclerosis · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Effects of naloxegol on transit recovery in patients undergoing cardiac surgery: A randomized, double-blind, placebo-controlled trial.
PMID 39988233 · Anaesth Crit Care Pain Med · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Extended Continuous Positive Airway Pressure in Preterm Infants Increases Lung Growth at 6 Months: A Randomized Controlled Trial.
PMID 39977011 · Am J Respir Crit Care Med · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials.
PMID 39969783 · Adv Ther · 2025-Apr
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.
PMID 39961315 · Lancet Diabetes Endocrinol · 2025-Apr
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India.
PMID 39950245 · Diabetes Obes Metab · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant-level analysis of the ONWARDS 1-5 trials.
PMID 39930546 · Diabetes Obes Metab · 2025-Apr
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.
PMID 39923271 · Eur Neuropsychopharmacol · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Outer Retinal Tubulation and Vision in Geographic Atrophy: A Natural History Analysis From the Phase 3 OAKS and DERBY Trials.
PMID 39918755 · Ophthalmic Surg Lasers Imaging Retina · 2025-Apr
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CLpro detected in the SCORPIO-SR phase 3 trial.
PMID 39892563 · Antiviral Res · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Meaningful change threshold estimation for the non-small cell lung cancer symptom assessment questionnaire (NSCLC-SAQ): psychometric analysis from a phase 3 trial (LIBRETTO-431).
PMID 39847268 · Qual Life Res · 2025-Apr
The record describes a psychometric analysis of a patient-reported outcome questionnaire from a Phase 3 randomized trial, but it does not report any primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR results, and it does not explicitly specify a drug intervention. Therefore, it does not meet the eligibility criteria for a drug-intervention oncology trial with time-to-event efficacy.
|
H
L
B
|
旧查询独有 |
needs_reviewmodel_uncertain |
pending
0 Figure · 0 Panel · risk -
|
|
Aprocitentan for Blood Pressure Reduction in Black Patients.
PMID 39840441 · Hypertension · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial.
PMID 39833645 · Pediatr Blood Cancer · 2025-Apr
原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
|
H
L
B
|
旧查询独有 |
eligiblephase3_publication_type |
needs_review
0 Figure · 0 Panel · risk not_assessed
|
|
Individualized transfusion decisions to minimize adverse cardiovascular outcomes in patients with acute myocardial infarction and anemia.
PMID 39826701 · Am Heart J · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.
PMID 39821928 · Diabetes Obes Metab · 2025-Apr
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.
PMID 39820580 · Diabetologia · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.
PMID 39800203 · Am J Ophthalmol · 2025-Apr
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial.
PMID 39797697 · BJU Int · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.
PMID 39789843 · Diabetes Obes Metab · 2025-Apr
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial.
PMID 39781601 · Diabetes Obes Metab · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial.
PMID 39722400 · J Am Acad Dermatol · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial.
PMID 39708985 · Gastroenterology · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Association that Neuroimaging and Clinical Measures Have with Change in Arm Impairment in a Phase 3 Stroke Recovery Trial.
PMID 39676623 · Ann Neurol · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).
PMID 39674398 · Int J Infect Dis · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.
PMID 39648559 · Liver Int · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR.
PMID 39645016 · J Heart Lung Transplant · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
PMID 39608389 · Lancet Infect Dis · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Dietary Habits of Individuals With Primary Sclerosing Cholangitis-Poor Fat-Soluble Vitamin Intake and Dietary Quality.
PMID 39601354 · Liver Int · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis.
PMID 39592058 · J Am Acad Dermatol · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Visual Loss in Geographic Atrophy: Learnings from the Lampalizumab Trials.
PMID 39581330 · Ophthalmology · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD.
PMID 39521398 · Am J Kidney Dis · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study.
PMID 39521012 · Lancet Infect Dis · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections.
PMID 39447871 · Ophthalmol Retina · 2025-Apr
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration: A Phase III Randomized Trial.
PMID 39389463 · Ophthalmol Retina · 2025-Apr
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Health-related quality of life in cutaneous T-cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome.
PMID 39315857 · J Eur Acad Dermatol Venereol · 2025-Apr
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
B
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Fixed-Dose Brexpiprazole and Sertraline Combination Therapy for the Treatment of Posttraumatic Stress Disorder: A Phase 3, Randomized Trial.
PMID 40982703 · J Clin Psychopharmacol · 2025 Nov
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial.
PMID 40193234 · J Addict Med · 2025 Nov
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Exploring Opioid Use Disorder Outcomes by Quantitative Urinalysis: Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.
PMID 39629836 · J Addict Med · 2025 May
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Testosterone plus lifestyle therapy improves skeletal muscle glycolysis in older men with obesity and hypogonadism.
PMID 41716487 · Front Endocrinol (Lausanne) · 2025
未发现恶性肿瘤人群证据。
|
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial.
PMID 41624863 · Front Immunol · 2025
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Association Between Cytomegalovirus Viremia Clearance and Post-Solid Organ Transplant Mortality in Patients With Refractory Cytomegalovirus Infection: SOLSTICE Post Hoc Analysis.
PMID 41384277 · Transpl Int · 2025
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Antibody response to tetanus, diphtheria, poliomyelitis, hepatitis B, and H. influenzae b vaccines in allogeneic hematopoietic stem cell transplant adult recipients: A multicenter trial.
PMID 41144397 · PLoS One · 2025
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone.
PMID 41080970 · Gates Open Res · 2025
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Bowel Preparation for Colonoscopy: The Patient Point of View.
PMID 41021426 · Dig Dis · 2025
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial.
PMID 40971945 · PLoS One · 2025
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Generic Intravenous Amisulpride (QLG2069) for the Prevention of Postoperative Nausea and Vomiting in Adults: A Phase III, Multicenter, Randomized, Placebo-Controlled Study.
PMID 40923005 · Drug Des Devel Ther · 2025
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants.
PMID 40713231 · J Clin Lipidol · 2025
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury.
PMID 40638707 · PLoS One · 2025
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
The PD COMM Process Evaluation: Describing Interventions and Implementation in a UK Pragmatic Randomised Controlled Trial of Speech and Language Therapy for People With Parkinson's-Related Dysarthria.
PMID 40637984 · Int J Lang Commun Disord · 2025
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials.
PMID 40602386 · Dermatology · 2025
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|